PMID- 33123469
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201031
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Interferon-Induced Protein 44 Correlated With Immune Infiltration Serves as a 
      Potential Prognostic Indicator in Head and Neck Squamous Cell Carcinoma.
PG  - 557157
LID - 10.3389/fonc.2020.557157 [doi]
LID - 557157
AB  - Interferon-induced protein 44 (IFI44) containing a guanosine-5'-triphosphate 
      (GTP) binding domain was reported to play a significant role in the immune 
      response to autoimmune disease. However, its roles involved in cancers remain 
      unclear. Here, we detected the expression of IFI44 in The Cancer Genome Atlas 
      (TCGA) Pan-cancer and generally explored the effect of IFI44 on immune 
      infiltration in the tumor microenvironment (TME). The results displayed that 
      IFI44 was mainly located in the cytoplasm and overexpressed in head and neck 
      squamous cell carcinoma (HNSC) samples compared with normal tissues. Survival 
      analysis exhibited that IFI44 was remarkably associated with the clinical 
      outcomes, particularly in lymph node-positive and locally advanced HNSC patients. 
      Biological analysis showed that IFI44 was correlated with such immune biological 
      processes as antigen-presenting and nuclear factor (NF)-kappa B signaling 
      pathways. Immune signature analysis demonstrated that the expression of IFI44 was 
      positively correlated with the infiltration of CD4(+) cells and macrophages as 
      well as neutrophils in HNSC. Taken together, these data suggested that IFI44 was 
      abnormally expressed in cancer tissues and indicated the potential impact of 
      IFI44 on the tumor immune infiltration in HNSC.
CI  - Copyright (c) 2020 Pan, Wang, Huang, Dai, Yang, Liang, Wu, Zhang, Huang, Yuan, Wu, 
      Wang, Liao, Huang and Guan.
FAU - Pan, Hua
AU  - Pan H
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Wang, Xiaoqing
AU  - Wang X
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Huang, Weiqiang
AU  - Huang W
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Dai, Yongmei
AU  - Dai Y
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
AD  - Department of Oncology, Fujian Provincial Hospital, Fuzhou, China.
FAU - Yang, Mi
AU  - Yang M
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Liang, Huazhen
AU  - Liang H
AD  - Department of Oncology, Maoming People's Hospital, Maoming, China.
FAU - Wu, Xixi
AU  - Wu X
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Zhang, Longshan
AU  - Zhang L
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Huang, Wenqi
AU  - Huang W
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Yuan, Lu
AU  - Yuan L
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Wu, Yuting
AU  - Wu Y
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Wang, Yin
AU  - Wang Y
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Liao, Liwei
AU  - Liao L
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Huang, Jihong
AU  - Huang J
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Guan, Jian
AU  - Guan J
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20201006
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7573551
OTO - NOTNLM
OT  - IFI44
OT  - head and neck squamous cell carcinoma
OT  - immune infiltration
OT  - locally advanced
OT  - poor prognosis
EDAT- 2020/10/31 06:00
MHDA- 2020/10/31 06:01
PMCR- 2020/01/01
CRDT- 2020/10/30 05:55
PHST- 2020/05/01 00:00 [received]
PHST- 2020/08/27 00:00 [accepted]
PHST- 2020/10/30 05:55 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2020/10/31 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.557157 [doi]
PST - epublish
SO  - Front Oncol. 2020 Oct 6;10:557157. doi: 10.3389/fonc.2020.557157. eCollection 
      2020.